CELLECTISAct. Nom. Aktie [WKN DE: A0MKPR / ISIN: FR0010425595]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu CELLECTISAct. Nom.

04.03.20		Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products (Businesswire)
03.03.20		Ausblick: CELLECTISAct Nom gewährt Anlegern Blick in die Bücher (finanzen.net)
25.02.20		Cellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday, March 5, 2020 at 7:30 AM EST (Businesswire)
18.02.20		Cellectis and Servier Expand Collaboration on UCART19 Products (Businesswire)
15.01.20		First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia (Businesswire)
06.01.20		Cellectis: An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery (Businesswire)
02.12.19		1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (Businesswire)
20.11.19		Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells (Businesswire)
13.11.19		Cellectis Publishes Creation of "Smart CAR T-Cells” for Potentially Safer, More Effective Treatments for Cancer in Nature Communications (Businesswire)
06.11.19		Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019 (Businesswire)
31.10.19		Cellectis to Hold Third Quarter and First Nine Months 2019 Earnings Call on Thursday, November 7, 2019 at 8:00 AM EST (Businesswire)
29.10.19		First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma (Businesswire)
01.10.19		Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates (Businesswire)
06.08.19		Cellectis Reports Financial Results for Second Quarter and First Six Months 2019 (Businesswire)
08.07.19		Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way (Businesswire)
26.06.19		Cellectis S.A. Reports Results from Combined Shareholders Meeting Held on June 25, 2019 (Businesswire)
07.05.19		Cellectis Reports Financial Results for First Quarter 2019 (Businesswire)
02.04.19		FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients (Businesswire)
11.03.19		Cellectis Reports 4th Quarter and Full Year 2018 Financial Results (Businesswire)
07.03.19		Cellectis Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART Portfolio (Businesswire)
25.02.19		Cellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry (Businesswire)
10.12.18		Cellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing (Businesswire)
13.11.18		Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018 (Businesswire)
19.09.18		CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board (Businesswire)
18.09.18		Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP (Businesswire)
02.08.18		Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer (Businesswire)
01.08.18		Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018 (Businesswire)
27.06.18		Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2018 (Businesswire)
12.06.18		Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports (Businesswire)
04.06.18		FDA Grants Cellectis IND Approval for UCART22 in B-ALL (Businesswire)
23.05.18		INSERTING and REPLACING: Approval of UCART123 Amendment in AML to Accelerate Clinical Development (Businesswire)
22.05.18		Cellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical Development (Businesswire)
21.05.18		Cellectis S.A.: Calyxt Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares (Businesswire)
15.05.18		Calyxt Announces Launch of Proposed Follow-On Offering (Businesswire)
10.05.18		Cellectis to Present Data at the 2018 ASGCT Annual Meeting (Businesswire)
07.05.18		Cellectis Reports 1st Quarter 2018 Financial Results (Businesswire)
02.05.18		Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL) (Businesswire)
01.05.18		Harvard’s Wyss Institute Partners with Cellectis to Recode the Human Genome (Businesswire)
11.04.18		Cellectis to Present Data at the 2018 AACR Annual Meeting (Businesswire)
10.04.18		Cellectis Announces Closing of Follow-On Offering (Businesswire)
05.04.18		Cellectis Announces Pricing of Follow-On Offering (Businesswire)
03.04.18		Cellectis Announces Launch of Follow-On Offering (Businesswire)
03.04.18		Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies (Businesswire)
13.03.18		Dr. Mathieu Simon to Retire as Cellectis’ Chief Operating Officer; Elsy Boglioli Named as Successor (Businesswire)
12.03.18		Cellectis Reports 4th Quarter and Full Year 2017 Financial Results (Businesswire)
08.03.18		Cellectis: Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting (Businesswire)
13.02.18		Two Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells (Businesswire)
06.02.18		Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
08.01.18		Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
02.01.18		Cellectis to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:00 P.M. PT (Businesswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Elon Musk prognostiziert Kursrückgang bei Bitcoin

Solana Kurs Prognose: 1.000 US-Dollar in 2025?

Palantir-Aktie nach Gewinn- und Umsatzplus deutlich höher

100.000-Dollar-Schwelle unterschritten: Bitcoin gibt nach

DeepSeek sorgt für Turbulenzen an den Krypto-Märkten - Crash oder Kaufgelegenheit?

Bitcoin, Ether und Co. im Check - ChatGPTs Top-Kryptowährung für 2025

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	04.02.2025 12:33
Kaufwert:	EUR
	Hinzufügen Speichern